# VRTX vs MRNA: Fair Value Comparison

Source: https://www.equity-rank.com/compare/vrtx-vs-mrna

Vertex Pharmaceuticals Inc vs. Moderna Inc · Biotechnology

VRTX's model fair value sits 20.9% below its current price; MRNA's model fair value sits 95.1% below its current price. Of the two, VRTX trades further below its model estimate. Model estimates under stated assumptions. Data as of 2026-11-09.

|  | [VRTX](https://www.equity-rank.com/stocks/VRTX) | [MRNA](https://www.equity-rank.com/stocks/MRNA) |
| --- | --- | --- |
| Price | $550.87 | $269.00 |
| Model fair value (multi-method blend) | $435.72 | $13.09 |
| Model fair value differential | -20.9% | -95.1% |
| Methods with a model value above price | 7 of 8 | 2 of 2 |
| Fundamental strength | B+ | C- |
| Next earnings report | — | — |

Differential = model fair value versus the current price; positive means the price sits below the model estimate.

## More comparisons

[VRTX vs REGN](https://www.equity-rank.com/compare/vrtx-vs-regn) · [VRTX vs RPRX](https://www.equity-rank.com/compare/vrtx-vs-rprx) · [MRNA vs REGN](https://www.equity-rank.com/compare/mrna-vs-regn) · [MRNA vs RPRX](https://www.equity-rank.com/compare/mrna-vs-rprx) · [All Biotechnology stocks](https://www.equity-rank.com/stocks/industry/biotechnology) · [Compare any two stocks](https://www.equity-rank.com/compare)

---

Fair value is a model estimate under stated assumptions — not a price target, not a prediction, and not a recommendation. This page is research information, not investment advice. Equity Rank is not a registered investment adviser.